Markets:

Overview

News

Currencies

International

Treasuries

Arena Pharmaceuticals, Inc. - Common Stock (NQ:ARNA)

N/A UNCHANGED

Last Price Updated: 4:00 PM EST, Mar 10, 2022 Add to My Watchlist

Quote

Overview Detailed Quote Charting Historical Prices

News

All News News Headlines Press Releases

Research

Quarterly Reports Insider Filings Other Filings

Press Releases about Arena Pharmaceuticals, Inc. - Common Stock

< Previous 1 2 Next >

Arena Pharmaceuticals Inc. (ARNA) Climbs to Annual-High Share Price

March 10, 2022

Via Investor Brand Network

Arena Pharmaceuticals Inc. (ARNA) Climbs to Annual-High Share Price

March 10, 2022

Via Investor Brand Network

Arena Reports Fourth Quarter and Full Year 2021 Financial Results and Key Program Updates

February 23, 2022

From Arena Pharmaceuticals, Inc.

Via Business Wire

Arena Pharmaceuticals Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

February 17, 2022

From Arena Pharmaceuticals, Inc.

Via Business Wire

Arena Pharmaceuticals to Release Fourth Quarter and Full-Year 2021 Financial Results and Provide Corporate Update on February 23

February 09, 2022

From Arena Pharmaceuticals, Inc.

Via Business Wire

Arena Pharmaceuticals Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

January 18, 2022

From Arena Pharmaceuticals, Inc.

Via Business Wire

Arena Pharmaceuticals Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

December 21, 2021

From Arena Pharmaceuticals, Inc.

Via Business Wire

Arena Merger Investigation: Halper Sadeh LLP Announces Investigation Into Whether the Sale of Arena Pharmaceuticals, Inc. Is Fair to Shareholders; Investors Are Encouraged to Contact the Firm – ARNA

December 13, 2021

From Halper Sadeh LLP

Via Business Wire

Pfizer to Acquire Arena Pharmaceuticals

December 13, 2021

From Pfizer Inc.

Via Business Wire

Arena Pharmaceuticals Achieves Target Enrollment for Etrasimod CULTIVATE Study A

November 19, 2021

From Arena Pharmaceuticals, Inc.

Via Business Wire

Arena Pharmaceuticals Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

November 16, 2021

From Arena Pharmaceuticals, Inc.

Via Business Wire

Arena Reports Third Quarter Financial Results and Key Program Updates

November 04, 2021

From Arena Pharmaceuticals, Inc.

Via Business Wire

Arena Pharmaceuticals Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

October 21, 2021

From Arena Pharmaceuticals, Inc.

Via Business Wire

Arena Pharmaceuticals to Release Third Quarter 2021 Financial Results and Provide Corporate Update on November 4

October 14, 2021

From Arena Pharmaceuticals, Inc.

Via Business Wire

Arena Pharmaceuticals Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

September 17, 2021

From Arena Pharmaceuticals, Inc.

Via Business Wire

Arena Pharmaceuticals to Host Virtual R&D Investor Calls and Participate in Upcoming September Investor Conferences

September 02, 2021

From Arena Pharmaceuticals, Inc.

Via Business Wire

Arena Pharmaceuticals Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

August 18, 2021

From Arena Pharmaceuticals, Inc.

Via Business Wire

Arena Reports Second Quarter Financial Results and Key Program Updates

August 05, 2021

From Arena Pharmaceuticals, Inc.

Via Business Wire

Arena Pharmaceuticals to Release Second Quarter 2021 Financial Results and Provide Corporate Update on August 5

July 29, 2021

From Arena Pharmaceuticals, Inc.

Via Business Wire

Arena Pharmaceuticals and Aristea Therapeutics Establish Collaboration for Development of RIST4721 for Treatment of Serious Immune-Mediated Inflammatory Diseases

July 27, 2021

From Arena Pharmaceuticals, Inc.

Via Business Wire

Arena Pharmaceuticals Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

July 22, 2021

From Arena Pharmaceuticals, Inc.

Via Business Wire

Arena Pharmaceuticals Appoints Doug Manion, M.D., F.R.C.P. (C), as Executive Vice President of Research & Development

July 19, 2021

From Arena Pharmaceuticals, Inc.

Via Business Wire

Arena Pharmaceuticals Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

June 18, 2021

From Arena Pharmaceuticals, Inc.

Via Business Wire

Steven Schoch Elected to Arena Pharmaceuticals Board of Directors

June 14, 2021

From Arena Pharmaceuticals, Inc.

Via Business Wire

Arena Pharmaceuticals Announces Orphan Drug Designation for Etrasimod for the Treatment of Eosinophilic Esophagitis (EoE)

June 09, 2021

From Arena Pharmaceuticals, Inc.

Via Business Wire

Rapid Development of Cannabinoid Based Medicinal Products Reaching New Levels

June 08, 2021

Via FinancialNewsMedia

Topics Cannabis Economy

Arena Pharmaceuticals Announces First Participant Randomized in Phase 2 Trial Evaluating Temanogrel in Coronary Microvascular Obstruction (cMVO)

June 08, 2021

From Arena Pharmaceuticals, Inc.

Via Business Wire

Arena Pharmaceuticals Earns "A" Rating from MSCI ESG, a Leading Rating Agency for Sustainable Investments

June 03, 2021

From Arena Pharmaceuticals, Inc.

Via Business Wire

Arena Pharmaceuticals Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

May 19, 2021

From Arena Pharmaceuticals, Inc.

Via Business Wire

Arena Pharmaceuticals Earns Prime Status from ISS ESG, a Leading Rating Agency for Sustainable Investments

May 12, 2021

From Arena Pharmaceuticals, Inc.

Via Business Wire

< Previous 1 2 Next >

Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.